This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2020
ASCO 2020
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2020 Bladder Cancer
Viewing 1-20 of 29 articles
ASCO 2020: Genitourinary Cancers Highlights – Kidney and Bladder
ASCO 2020: Checkpoint Inhibition in Metastatic Urothelial Carcinoma: Timing is Everything
ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma
ASCO 2020: DUTRENEO Trial: A Randomized Phase II Trial of DUrvalumab and TREmelimumab Versus Chemotherapy as a NEOadjuvant Approach to Muscle-Invasive Urothelial Bladder Cancer Patients Prospectively Selected by an Interferon-Gamma Immune Signature
ASCO 2020: Discussant: Novel Immunotherapy-Based Therapy in Metastatic Urothelial Cancers and Rare Genitourinary Malignancies
ASCO 2020: Phase II Neoadjuvant Gemcitabine and Pembrolizumab for Locally Advanced Urothelial Cancer: Interim Results from the Cisplatin-Ineligible Cohort of GU14-188
ASCO 2020: New and Updated Pivotal Trials of Single Agent and Combination Immunocheckpoint Blockers in Bladder and Kidney Cancers
ASCO 2020: Single Agent Targeted Agents vs Combinations with IO: What is the Optimal Future Therapy in Advanced Urothelial Cancer?
ASCO 2020: Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers
ASCO 2020: Emerging Biomarkers of Checkpoint Inhibitors-Based Combinations in Urothelial Cancer
ASCO 2020: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605
ASCO 2020: Association of Molecular Subtypes with Pathologic Response Interface to Studying of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle Invasive Bladder Cancer
ASCO 2020: Safety and Preliminary Efficacy of Rogaratinib in Combination with Atezolizumab in a Phase IbII Study (FORT-2) of First-Line Treatment in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic UC and FGFR mRNA Overexpression
ASCO 2020: ERDAFITINIB in Locally Advanced or Metastatic Urothelial Carcinoma: Long-Term Outcomes in BLC2001
ASCO 2020: Cabozantinib in Combination with Atezolizumab in Urothelial Carcinoma Previously Treated with Platinum-Containing Chemotherapy: Results from Cohort 2 of the COSMIC-021 Study
ASCO 2020: A Phase III Randomized Study of Neoadjuvant Chemotherapy Alone or in Combination with Nivolumab ± Linrodostat Mesylate, Followed by Adjuvant Postsurgical Nivolumab ± Linrodostat, in Cisplatin-Eligible Muscle Invasive Bladder Cancer
ASCO 2020: Phase II Trial of Durvalumab plus Tremelimumab with Concurrent Radiotherapy as Bladder-Sparing Therapy in Patients with Localized Muscle Invasive Bladder Cancer: A SOGUG Study.
ASCO 2020: Study EV-103: New Randomized Cohort Testing Enfortumab Vedotin as Monotherapy or in Combination with Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer (Trial in Progress)
ASCO 2020: Pembrolizumab for the Treatment of Patients with Bacillus Calmette-Guérin Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer: Over Two Years Follow-Up of KEYNOTE-057
ASCO 2020: Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Cancer: Implications for Value-Based Pricing
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free